Skip to main content

What medicines should not be taken with Stribild?

Medically reviewed by Carmen Pope, BPharm. Last updated on Aug 27, 2024.

Official Answer by Drugs.com

Stribild is a combination tablet containing elvitegravir, emtricitabine, tenofovir disoproxil fumarate (TDF), and cobicistat.

Stribild has the potential to interact with many other drugs, mainly because of its cobicistat component. Cobicistat is a potent inhibitor of cytochrome P450 3A and 2D6 enzymes, and also inhibits the following transporters P-glycoprotein (P-gp), BCRP, OATP1B1, and OATP1B3, which can affect the absorption of other medications, increasing their concentration in the blood.

Common medications that may interact with Stribild include:

Related questions

References

Read next

Can Stribild be crushed?

Yes, Stribild tablets can be crushed or cut to ease administration to people who have difficulty swallowing the tablets. The effects of crushing Stribild and then combining the crushed tablet with liquid nutrition were investigated in 24 volunteers. There was no difference in most pharmacokinetic parameters, such as area under the curve between the people receiving crushed Stribild and those receiving a whole tablet with breakfast. A difference in the maximum concentration of Stribild was noted between the two groups, but this was considered not clinically relevant. People with swallowing difficulties or needing liquid feeding can safely use crushed and suspended Stribild tablets. Continue reading

How long does it take for Stribild to work?

Stribild works quickly to drop levels of HIV-1 in the blood; however, it may take several months for viral loads to become undetectable (defined in clinical studies using Stribild as an HIV-1 RNA of <50 copies/mL). Most Stribild studies were a minimum of 48 weeks duration and these showed that 94% of people with HIV-1 taking Stribild achieved undetectable viral loads. Continue reading

Can Descovy be used for pre-exposure prophylaxis (PrEP) in HIV?

Yes. The FDA approved Descovy (emtricitabine and tenofovir alafenamide) for pre-exposure prophylaxis (PrEP) in October 2019 to help reduce the risk of HIV-1 infection. Continue reading

See also:

Related medical questions

Drug information

Related support groups